Government Pricing and Market Access Fraud: The Calculation Behind the Certification

Government pricing fraud hides drug discounts, mislabels fees or changes a calculation to underpay Medicaid rebates or inflate Medicare reimbursement. A government pricing whistleblower may negotiate the contract, process the rebate or calculate the price that management certifies. The customer received a benefit. The government-facing number left it out. The shortfall falls on public health care programs and the taxpayers who fund them.

The useful evidence often sits behind the reported price: the agreement, the customer payment, the treatment in the pricing system and the decision to keep reporting it that way. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Which Government Price Does Your Calculation Move?

Average Manufacturer Price, Best Price and Average Sales Price affect different government payments. The same transaction can receive different treatment under each calculation, so the program and the price field matter as much as the amount.

Average Manufacturer Price, usually called AMP, measures prices in the retail community pharmacy channel. Medicaid uses AMP and Best Price to determine the quarterly manufacturer rebate owed to states. Best Price captures the lowest qualifying price, including applicable discounts, rebates and contingent free goods. A discount omitted from that calculation can leave Medicaid with less than it is owed.

Average Sales Price, or ASP, feeds Medicare Part B reimbursement. A manufacturer that leaves a qualifying customer concession out of ASP can make the reported price too high. A payment to a distributor can matter even when the physician’s invoice shows no change.

An error in AMP or the Medicaid unit rebate amount also changes the 340B ceiling price paid by safety-net providers.

The public list price and the net price paid by healthcare purchasers also differ. Rebates and other concessions can arrive after the sale. That is why the employee who processes the later payment may see something the original invoice never showed.

Manufacturer Government Price Certification and the False Calculation

A manufacturer government price certification can carry a false calculation built from decisions made well before the report reaches the person signing it. For Medicaid price reports, the certifier is the chief executive officer, chief financial officer, an equivalent officer or a direct delegate. The underlying assumptions and transaction treatment give that signature its meaning.

A bona fide service fee pays fair market value for specific work actually done for the manufacturer, work it would otherwise do or buy. The recipient must keep the fee rather than pass it to a customer. A pricing analyst needs to know what the payment bought and where it ended up.

The incentive can run in opposite directions. Treating a genuine wholesaler service fee as a discount can push Average Manufacturer Price down and reduce Medicaid rebates. Treating a customer discount as a service fee can keep it out of Average Sales Price and leave Medicare reimbursement too high.

In its September 2019 report on reasonable assumptions, the Department of Health and Human Services’ Inspector General described how the Centers for Medicare & Medicaid Services historically told manufacturers not to submit those assumptions and reviewed them case by case. The explanation for a reported number could remain inside the company while government payments continued to depend on it.

The ASP reporting requirements effective January 1, 2026 added reasonable assumptions, documentation of the method used to determine fair market value, and a certification from the service-fee recipient that the fee was not passed to a customer. Those records put the manufacturer’s treatment beside the counterparty’s account of the same payment.

Where Government Pricing Fraud Shows up Inside the Company

Contracting staff see the promised terms. Government pricing staff see how those terms enter AMP, ASP or Best Price. Rebate operations sees the payment, and finance or compliance may see the discrepancy raised before the next certification. The cases show why each view matters.

Contracting and National Accounts

King Pharmaceuticals’ former director of contracts and national accounts was the whistleblower in a case resolved by a settlement in 2005. The government alleged inaccurate AMP and Best Price reporting across the company’s product line, leaving Medicaid short on rebates and overcharging federal purchasers and Public Health Service programs.

King agreed to redo pricing across its product line. The government attributed the alleged misreporting to inadequate internal systems and controls. For someone in national accounts, the connection between negotiated customer terms and the system that reports government prices can reach well beyond one disputed invoice.

Government Pricing and Wholesaler Fees

A pharmacist brought the case in which AstraZeneca and Cephalon settled allegations of improperly deducting wholesaler service fees from AMP. The alleged result was smaller quarterly Medicaid rebates.

The same whistleblower’s case against Bristol-Myers Squibb ended in a settlement in 2021. The allegations concerned both wholesaler-fee deductions and excluded price-appreciation value. For the pricing team, the wholesaler agreement and the calculation’s treatment of its payments belong in the same conversation.

Hospital Bundles and the Medicaid Rebate Calculation

A market access employee may see the hospital bundle before anyone checks its treatment in the rebate calculation. Discounts tied across products have to be allocated across the arrangement for Best Price. A concession used to win hospital business can therefore change what the manufacturer owes Medicaid.

Wyeth and Pfizer settled in 2016 to resolve allegations that Wyeth omitted bundled discounts on oral and intravenous Protonix from Best Price. The government alleged that the bundle encouraged hospitals to use the oral drug.

The attraction extended beyond the hospital stay. According to the government’s account, patients discharged on Protonix Oral were likely to keep taking it, with Medicaid and other payers paying nearly full price. The hospital discount helped win the later outpatient business. The alleged omission then denied Medicaid the rebate benefit of that discount.

For an insider, the oral and intravenous contracts, the condition tying their discounts together and the allocation in Best Price explain the transaction. Reading each product’s price alone can miss what the hospital received for buying the pair.

A separate complaint against Endo alleged an even more personal route to formulary access: free Lidoderm for a pharmacy director’s mother, in exchange for the director using his influence to obtain preferred placement. The whistleblower’s complaint also alleged that the contingent free drugs were omitted from Best Price. The benefit, the purchasing influence and the reported price were parts of the same allegation.

Nominal-price abuse can hide the same hospital incentive under another label. The Justice Department alleged that Merck improperly called hospital discounts nominal prices and left them out of its government reports. Its Pepcid discounts allegedly bought preferred hospital use and the outpatient prescriptions that followed. The commercial benefit reached beyond the hospital, while Medicaid lost the benefit of the discount.

Rebate Operations Sees What the Contract Actually Paid

A pharmaceutical rebate operations employee can connect the contract’s promised payment to the rebate that moved and the category used in the government report. A payment described as a service fee calls for the service agreement and the work behind it.

Rite Aid and Elixir reached a 2024 settlement with the United States resolving allegations that retained manufacturer rebates were improperly reported as bona fide service fees. The government alleged that manufacturers had not negotiated to pay those fees and that Elixir knew the retained rebates did not meet the definition. A former RX Options employee brought the whistleblower case.

These were Medicare Part D reports about rebates and other remuneration, used in reconciling government payments. The manufacturer contract, the retained amount and the plan’s report carried different parts of the story. The alleged service fee had a reporting advantage without the negotiated service-fee arrangement behind it.

Market access explains why these payments exist in the first place. Pharmacy benefit managers negotiate manufacturer rebates for drug plans, and formulary access and tier placement are major bargaining points. A September 2023 Government Accountability Office report found that formulary access and tier placement accounted for most of the manufacturer rebates categorized by Part D plan sponsors for 2021. Placement on the plan’s drug list is something manufacturers pay to obtain.

The USC Schaeffer Center’s 2020 paper, The Association Between Drug Rebates and List Prices, found that increases in rebates were associated with increases in list prices. The relationship persisted after accounting for drug-class time trends and excluding drugs with high Medicaid shares. That finding explains why a larger rebate can sit beside a higher public price.

When the Final Price Arrives After the Sale

Some contracts settle the price after the manufacturer reviews how the drug was used. Indication-Specific Drug Pricing–Simple in Theory, Complex in Reality, published in Managed Care in 2018, describes a weighted-average price based on expected uses, followed by retrospective reconciliation through rebates.

The article identifies a practical obstacle: the indication may sit in the medical record without appearing in the dispensing transaction. Contracting, utilization data and rebate operations then each hold part of the price calculation. We connect the contract to the completed reconciliation when assessing a pricing whistleblower case.

ASP Reporting and Customer Credit Card Fee Records

For an ASP reporting analyst, customer credit card fee records can show a benefit missing from the reported price. The government’s April 2024 complaint announcement against Regeneron alleged that it paid distributors’ processing fees for physician-customers buying Eylea, then omitted those payments from ASP price concessions.

The government alleged that physicians could pay the lower cash price while using credit cards and receiving card rewards. It also alleged that Regeneron tried to disguise the payments as bona fide service fees despite knowing they did not qualify.

The whistleblowers’ complaint describes the distributor arrangement this way:

That complaint also points to an internal ASP spreadsheet identifying rebates allegedly left out of reported prices. The distribution agreement, fee payments, customer benefit and spreadsheet connect the commercial arrangement to the government number. The invoice could stay the same while the customer received more.

When Management Knows What the Calculation Leaves Out

A government pricing analyst who sees an excluded discount ignored by management may know both the reporting treatment and the decision to preserve it. We examine the calculation alongside the warnings, internal discussions and instructions that explain who understood its effect.

The Acthar case shows the same knowledge question through a different input: the base AMP used to calculate inflation rebates. A whistleblower alleged that Mallinckrodt used a later, higher base price, leaving earlier price increases out of the rebate calculation. The complaint describes what happened after CMS challenged the reporting:

The complaint alleges that management had the calculation and chose to restrict discussion of it. Its answer to the rebate bill was to talk about it less.

In its March 2022 settlement, Mallinckrodt admitted that Acthar was not a new drug in 2013 and had been approved and marketed before 1990. It agreed to correct the base-date AMP. The drug’s earlier history mattered because the reported starting point determined which price increases generated rebates.

A Reported Price Can Also Become a Sales Tool

A reported benchmark can help sell the product when the customer expects reimbursement above its purchase cost. Average Wholesale Price, or AWP, supplies another example of why the actual sale and the reported number belong together.

In its complaint announcement concerning Professional Compounding Centers of America, the government alleged inflated ingredient prices. Its complaint alleged that senior managers told sales representatives to highlight the gap between reported AWP and actual selling prices to pharmacy customers. The larger reported price became part of the sales pitch. For someone in pricing or account management, that pitch connects the benchmark to the business it was intended to win.

What Evidence Is Needed to Prove Fraud?

Proving government pricing fraud means connecting the customer’s benefit to the certified number, the public money affected and who knew. That is the work we do with you, using the contracts, calculations and internal discussions your role helps you understand.

These cases turn on specific choices: a hospital discount left out of Best Price, a customer benefit labeled as a distributor service, a base price retained after a warning. Your knowledge of why the company chose that treatment can make the difference between a number on a report and an account of how public money went missing.

You Know How the Number Was Chosen

If you can explain the contract, the excluded payment or the warning behind a certified price, speak with our whistleblower experts about the calculation. We build the case around that knowledge and bring in pharmaceutical pricing whistleblower lawyers who understand manufacturer reporting and rebate disputes. We stay beside you from the first assessment through the case, connecting what your role reveals to the public money at stake.